Developer docs
API playgroundTry for free, no card

Search company profiles

JSR Life Sciences

Full company profile

uuid0006n17

Namestring
JSR Life Sciences
Legal namestring
JSR Life Sciences, LLC
Company typeenum
Private
Founded yearint
2012
Descriptiontext

JSR Life Sciences is the life sciences operating arm of Japan-based JSR Corporation, established in 2012 and headquartered in Sunnyvale, California, with operations spanning 28 sites across 7 countries. The company is structured as a portfolio of wholly-owned subsidiaries serving the biologics value chain: KBI Biopharma provides contract development and manufacturing (CDMO) services including mammalian and microbial production with 6x2000L single-use bioreactor capacity; Selexis SA offers the SUREtechnology Platform and PUREplatform for mammalian cell line and microbial expression development; MBL distributes in vitro diagnostic reagents primarily across APAC; and Crown Bioscience (being divested) provides CRO services in oncology and immuno-oncology, including the world's largest commercial PDX collection and exclusive HUB Organoid licensing.

The company's proprietary bioprocess product franchise centers on the Amsphere Protein A chromatography resin line — Amsphere A3 and the newer Amsphere A+ — engineered for downstream purification of therapeutic antibodies, with claimed up to 50% higher dynamic binding capacity than market standard and validated use in over 150 clinical drug product trials. Complementary products include the CELLiST BASAL CHO MX cell culture medium (co-developed with Ajinomoto Genematrix), the Chromassette modular chromatography platform, Magnosphere magnetic microparticles, and Blockmaster synthetic blocking reagents for diagnostics.

JSR Life Sciences operates a B2B enterprise sales model with direct field sales to pharmaceutical and biotechnology manufacturers, CRO/CDMO service delivery, and regional distribution (notably MBL in Japan). Pricing is quote-based under multi-year contracts with regulatory support files provided under NDA. The company is undergoing major portfolio reshaping: it divested its chromatography business to MilliporeSigma (Merck KGaA) in April 2026 and agreed to sell Crown Bioscience to Adicon (a Carlyle Group affiliate) for $204M, with closing scheduled for 2026, leaving KBI Biopharma, Selexis, and MBL as the retained core operations.

Short descriptiontext

JSR Life Sciences is a wholly-owned subsidiary of Japan-based JSR Corporation that provides bioprocess products and contract manufacturing and research services to biopharmaceutical companies globally through subsidiaries including KBI Biopharma (CDMO), Selexis (cell line development), and MBL (diagnostics).

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSunnyvale, United States
HQ citystring
Sunnyvale
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices8 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biopharmaceutical manufacturing services, contract development manufacturing, protein A chromatography resins, preclinical contract research, life sciences reagents
Industry4 codes
PRIMARYHLAGAGAI
Raw Materials & Critical Reagents Supply (Media/Resins/Cytokines)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAAAKAI
Raw Materials & Critical Reagents Supply Services (media, resins, single-use)
SECONDARYHLAGAKAJ
Manufacturing Quality Assurance & GMP Compliance (batch release, deviation/CAPA, tech transfer QA)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Regulatory Affairs, Quality & Compliance Services (GxP)
SECONDARYHLAGAGAL
GMP Quality, Validation & Regulatory Support (GMP/CSV/Qualification)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code3 codes
  • Services-Commercial Physical & Biological Research8731
  • Pharmaceutical Preparations2834
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Biopharmaceutical CDMO and CRO Services
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1Chromatography Resin Sales
TypeHardware Sales
Description

Sale of Amsphere™ brand Protein A chromatography resins (Amsphere A3, Amsphere A+) to biopharmaceutical manufacturers for downstream purification of antibodies and biologics. Products include resin slurry and pre-packed columns in various sizes.

jsrlifesciences.com
2Contract Research Services (CRO)
TypeProfessional Services
Description

Crown Bioscience provides discovery, preclinical, and translational research services including oncology and immuno-oncology drug discovery, PDX models, organoid services, and biomarker discovery to pharmaceutical and biotech companies.

jsrlifesciences.com
3Contract Manufacturing Services (CDMO)
TypeProfessional Services
Description

KBI Biopharma provides fully-integrated drug development and biomanufacturing services from cell line development through commercial manufacturing, including mammalian and microbial production capabilities.

jsrlifesciences.com
4Cell Culture Media Products
TypeHardware Sales
Description

CELLiST™ BASAL CHO MX cell culture media product for biologics manufacturing, developed in partnership with Ajinomoto Genematrix.

jsrlifesciences.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain, Marketing or Sales
Pricing details1 tier
1Custom quotation-based pricing for Amsphere chromatography resins and services
ModelOtherBilling cadenceMulti-year contract
Notes

Quote-based / Not publicly disclosed. Pre-packed columns and resin slurry available in multiple sizes. Regulatory Support Files available under NDA.

jsrlifesciences.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 12 records shown
1Amsphere
Description

Protein A chromatography resin product line for advanced protein separation in downstream processing of therapeutic antibodies.

jsrlifesciences.com
+11 more records
Core offering1 text field

JSR Life Sciences provides materials and integrated services that enable biopharmaceutical manufacturing and life science research. Its offerings span proprietary Protein A chromatography resins (Amsphere A3, Amsphere A+), cell culture media, in vitro diagnostic reagents, and contract services through subsidiaries: KBI Biopharma (CDMO for biologics development and manufacturing) and Crown Bioscience (CRO for oncology and immuno-oncology preclinical research).

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Up to 50% higher dynamic binding capacity (DBC) compared to market standard at 2-6 minute residence times
+4 more records
Product and service1 record
1Amsphere A3 Protein A Chromatography Resin
Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Pfizer and JSR Life Sciences have both introduced advanced Protein A resin products in the Japan market to enhance purification performance for monoclonal antibody production.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

JSR and KBI Biopharma collaborated with Ajinomoto Genematrix to develop CELLiST BASAL CHO-MX cell culture media, which Ajinomoto Genematrix commercialized as a product for high-performance CHO cell culture.

Strategic tierCoreTypeTechnology or Integration
Description

Crown Bioscience is the only licensed preclinical CRO service provider for HUB Organoid technology, enabling tumor organoid services for drug discovery and development.

4Keio University
Strategic tierStrategicTypeStrategic or Co-development Partner
Description

JSR-Keio University Medical and Chemical Innovation Center (JKiC) enables collaboration between JSR Group researchers and Keio University School of Medicine researchers for medical-engineering innovation in diagnostics and therapeutics.

jsrlifesciences.com
5MilliporeSigma (Merck KGaA)
Strategic tierMajorTypeStrategic or Co-development Partner
Description

MilliporeSigma completed acquisition of JSR Life Sciences' chromatography business in April 2026, enhancing Merck's downstream purification capabilities for biopharmaceutical manufacturing and incorporating a team from Belgium to support antibody purification solutions.

pulse2.com
Recent move10 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Leading provider of chromatography resins (MabSelect Protein A), bioprocess equipment, and CDMO services. Direct competitor to the divested Amsphere franchise and to KBI in bioprocessing solutions.

TypeDirect peer
Description

Manufacturer of Protein A chromatography resins (TOYOPEARL AF-rProtein A) and other bioprocess media. Direct competitor to Amsphere in the Protein A resin market for mAb purification.

TypeBroad incumbent
Description

World's largest CDMO offering mammalian and microbial biologics manufacturing, cell and gene therapy services, and integrated development. Direct competitor to KBI Biopharma in biologics CDMO, but operates at much greater scale and modality breadth.

TypeBroad incumbent
Description

Large-scale Korean CDMO with massive bioreactor capacity for commercial biologics manufacturing. Competes with KBI Biopharma for mammalian cell culture contracts and offers similar end-to-end development services at much larger scale.

TypeBroad incumbent
Description

Global biologics CDMO with integrated discovery, development, and manufacturing services including cell line development. Directly comparable to KBI's CDMO offerings and operates globally with significantly larger capacity.

TypeBroad incumbent
Description

Major CDMO offering biologics development and manufacturing, including mammalian cell culture. Direct competitor to KBI Biopharma in biologics CDMO with broader service portfolio and global footprint.

TypeDirect peer
Description

Mammalian and microbial CDMO with similar scale to KBI Biopharma, offering cell line development through commercial manufacturing. Head-to-head competitor for mid-sized biologics CDMO contracts.

8MilliporeSigma (Merck KGaA Life Science)
TypeDirect peer
Description

Major supplier of chromatography resins, raw materials, and bioprocessing solutions. Now owns JSR's Amsphere chromatography business and competes with KBI in bioprocess services and consumables.

TypeBroad incumbent
Description

Major preclinical CRO offering oncology drug discovery, safety assessment, and research models. Direct competitor to divested Crown Bioscience in preclinical oncology CRO services.

TypeEmerging player
Description

Chinese-headquartered CRO/CDMO offering preclinical research and biologics manufacturing. Comparable to JSR Life Sciences' integrated CRO-CDMO model with strong APAC presence.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries6 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment2 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

JSR Life Sciences

Biopharmaceutical CDMO and CRO Servicesjsrlifesciences.com

JSR Life Sciences is a wholly-owned subsidiary of Japan-based JSR Corporation that provides bioprocess products and contract manufacturing and research services to biopharmaceutical companies globally through subsidiaries including KBI Biopharma (CDMO), Selexis (cell line development), and MBL (diagnostics).

What JSR Life Sciences does

JSR Life Sciences is the life sciences operating arm of Japan-based JSR Corporation, established in 2012 and headquartered in Sunnyvale, California, with operations spanning 28 sites across 7 countries. The company is structured as a portfolio of wholly-owned subsidiaries serving the biologics value chain: KBI Biopharma provides contract development and manufacturing (CDMO) services including mammalian and microbial production with 6x2000L single-use bioreactor capacity; Selexis SA offers the SUREtechnology Platform and PUREplatform for mammalian cell line and microbial expression development; MBL distributes in vitro diagnostic reagents primarily across APAC; and Crown Bioscience (being divested) provides CRO services in oncology and immuno-oncology, including the world's largest commercial PDX collection and exclusive HUB Organoid licensing.

The company's proprietary bioprocess product franchise centers on the Amsphere Protein A chromatography resin line — Amsphere A3 and the newer Amsphere A+ — engineered for downstream purification of therapeutic antibodies, with claimed up to 50% higher dynamic binding capacity than market standard and validated use in over 150 clinical drug product trials. Complementary products include the CELLiST BASAL CHO MX cell culture medium (co-developed with Ajinomoto Genematrix), the Chromassette modular chromatography platform, Magnosphere magnetic microparticles, and Blockmaster synthetic blocking reagents for diagnostics.

JSR Life Sciences operates a B2B enterprise sales model with direct field sales to pharmaceutical and biotechnology manufacturers, CRO/CDMO service delivery, and regional distribution (notably MBL in Japan). Pricing is quote-based under multi-year contracts with regulatory support files provided under NDA. The company is undergoing major portfolio reshaping: it divested its chromatography business to MilliporeSigma (Merck KGaA) in April 2026 and agreed to sell Crown Bioscience to Adicon (a Carlyle Group affiliate) for $204M, with closing scheduled for 2026, leaving KBI Biopharma, Selexis, and MBL as the retained core operations.

JSR Life Sciences firmographics

Firmographics
Name
JSR Life Sciences
Legal name
JSR Life Sciences, LLC
Website
https://jsrlifesciences.com
Company type
Private
Founded year
2012
Operating status
Operating
Headcount range
11–50 employees
Short description
JSR Life Sciences is a wholly-owned subsidiary of Japan-based JSR Corporation that provides bioprocess products and contract manufacturing and research services to biopharmaceutical companies globally through subsidiaries including KBI Biopharma (CDMO), Selexis (cell line development), and MBL (diagnostics).
Ownership category
akta.pro rank

JSR Life Sciences industry classification

Industry
Product category
Biopharmaceutical CDMO and CRO Services
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), In-Vitro Diagnostic Substance Manufacturing (325413)
SIC
Services-Commercial Physical & Biological Research (8731), Pharmaceutical Preparations (2834), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAGAGAI
Raw Materials & Critical Reagents Supply (Media/Resins/Cytokines)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAAAKAI
Raw Materials & Critical Reagents Supply Services (media, resins, single-use)
SECONDARYHLAGAKAJ
Manufacturing Quality Assurance & GMP Compliance (batch release, deviation/CAPA, tech transfer QA)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Regulatory Affairs, Quality & Compliance Services (GxP)
SECONDARYHLAGAGAL
GMP Quality, Validation & Regulatory Support (GMP/CSV/Qualification)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)

Keywords

  • Biopharmaceutical manufacturing services
  • Contract development manufacturing
  • Protein A chromatography resins
  • Preclinical contract research
  • Life sciences reagents

Where JSR Life Sciences is headquartered

Location

Headquarters

HQ city
Sunnyvale
HQ country
United States
HQ region
North America

Offices8 records

Markets served

JSR Life Sciences business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain, Marketing or Sales

Revenue model

  1. Chromatography Resin Sales: Sale of Amsphere™ brand Protein A chromatography resins (Amsphere A3, Amsphere A+) to biopharmaceutical manufacturers for downstream purification of antibodies and biologics. Products include resin slurry and pre-packed columns in various sizes.
  2. Contract Research Services (CRO): Crown Bioscience provides discovery, preclinical, and translational research services including oncology and immuno-oncology drug discovery, PDX models, organoid services, and biomarker discovery to pharmaceutical and biotech companies.
  3. Contract Manufacturing Services (CDMO): KBI Biopharma provides fully-integrated drug development and biomanufacturing services from cell line development through commercial manufacturing, including mammalian and microbial production capabilities.
  4. Cell Culture Media Products: CELLiST™ BASAL CHO MX cell culture media product for biologics manufacturing, developed in partnership with Ajinomoto Genematrix.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractCustom quotation-based pricing for Amsphere chromatography resins and services

Go-to-market motion2 records

Distribution channels4 records

Marketing channels6 records

JSR Life Sciences product offering

Product offering

Core offering

JSR Life Sciences provides materials and integrated services that enable biopharmaceutical manufacturing and life science research. Its offerings span proprietary Protein A chromatography resins (Amsphere A3, Amsphere A+), cell culture media, in vitro diagnostic reagents, and contract services through subsidiaries: KBI Biopharma (CDMO for biologics development and manufacturing) and Crown Bioscience (CRO for oncology and immuno-oncology preclinical research).

Differentiator

Problem solved

Functional benefit

Brands

  • Amsphere: Protein A chromatography resin product line for advanced protein separation in downstream processing of therapeutic antibodies.
  • Amsphere A3
  • Amsphere A+
  • CELLiST
  • ChromNeX
  • MBL (Medical and Biological Laboratories)
  • Crown Bioscience
  • KBI Biopharma
  • Selexis
  • IMMUTEX
  • Blockmaster
  • Magnosphere

Products and services

  • Amsphere A3 Protein A Chromatography Resin

Quantifiable outcome

  • Up to 50% higher dynamic binding capacity (DBC) compared to market standard at 2-6 minute residence times
  • +4 more outcomes

Companies that use JSR Life Sciences

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles3 records

JSR Life Sciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

JSR Life Sciences partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered minor, core, strategic and major.

  • PfizerminorStrategic or Co-development PartnerPfizer and JSR Life Sciences have both introduced advanced Protein A resin products in the Japan market to enhance purification performance for monoclonal antibody production.
  • Ajinomoto GenematrixcoreStrategic or Co-development PartnerJSR and KBI Biopharma collaborated with Ajinomoto Genematrix to develop CELLiST BASAL CHO-MX cell culture media, which Ajinomoto Genematrix commercialized as a product for high-performance CHO cell culture.
  • HUB Organoids (Hubrecht Organoid Technology)coreTechnology or IntegrationCrown Bioscience is the only licensed preclinical CRO service provider for HUB Organoid technology, enabling tumor organoid services for drug discovery and development.
  • Keio UniversitystrategicStrategic or Co-development PartnerJSR-Keio University Medical and Chemical Innovation Center (JKiC) enables collaboration between JSR Group researchers and Keio University School of Medicine researchers for medical-engineering innovation in diagnostics and therapeutics.
  • MilliporeSigma (Merck KGaA)majorStrategic or Co-development PartnerMilliporeSigma completed acquisition of JSR Life Sciences' chromatography business in April 2026, enhancing Merck's downstream purification capabilities for biopharmaceutical manufacturing and incorporating a team from Belgium to support antibody purification solutions.

Scale indicators11 records

Recent moves10 records

Expansion highlights6 records

JSR Life Sciences competitors and assessment

Company assessment

Broad incumbents

  • Cytiva (Danaher): Leading provider of chromatography resins (MabSelect Protein A), bioprocess equipment, and CDMO services. Direct competitor to the divested Amsphere franchise and to KBI in bioprocessing solutions.
  • Lonza Group: World's largest CDMO offering mammalian and microbial biologics manufacturing, cell and gene therapy services, and integrated development. Direct competitor to KBI Biopharma in biologics CDMO, but operates at much greater scale and modality breadth.
  • Samsung Biologics: Large-scale Korean CDMO with massive bioreactor capacity for commercial biologics manufacturing. Competes with KBI Biopharma for mammalian cell culture contracts and offers similar end-to-end development services at much larger scale.
  • WuXi Biologics: Global biologics CDMO with integrated discovery, development, and manufacturing services including cell line development. Directly comparable to KBI's CDMO offerings and operates globally with significantly larger capacity.
  • Catalent (Novo Holdings): Major CDMO offering biologics development and manufacturing, including mammalian cell culture. Direct competitor to KBI Biopharma in biologics CDMO with broader service portfolio and global footprint.
  • Charles River Laboratories: Major preclinical CRO offering oncology drug discovery, safety assessment, and research models. Direct competitor to divested Crown Bioscience in preclinical oncology CRO services.

Direct peers

  • Tosoh Bioscience: Manufacturer of Protein A chromatography resins (TOYOPEARL AF-rProtein A) and other bioprocess media. Direct competitor to Amsphere in the Protein A resin market for mAb purification.
  • AGC Biologics: Mammalian and microbial CDMO with similar scale to KBI Biopharma, offering cell line development through commercial manufacturing. Head-to-head competitor for mid-sized biologics CDMO contracts.
  • MilliporeSigma (Merck KGaA Life Science): Major supplier of chromatography resins, raw materials, and bioprocessing solutions. Now owns JSR's Amsphere chromatography business and competes with KBI in bioprocess services and consumables.

Emerging players

  • Pharmaron: Chinese-headquartered CRO/CDMO offering preclinical research and biologics manufacturing. Comparable to JSR Life Sciences' integrated CRO-CDMO model with strong APAC presence.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

JSR Life Sciences social profiles

Digital presence

JSR Life Sciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

JSR Life Sciences leadership team

Management profile

Number of profiles

Profiles4 records

JSR Life Sciences subsidiaries and ownership

Company hierarchy

Subsidiaries6 records

JSR Life Sciences funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

JSR Life Sciences M&A and investment

M&A and investment

M&A1 record

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about JSR Life Sciences

What does JSR Life Sciences do?

JSR Life Sciences provides materials and integrated services that enable biopharmaceutical manufacturing and life science research. Its offerings span proprietary Protein A chromatography resins (Amsphere A3, Amsphere A+), cell culture media, in vitro diagnostic reagents, and contract services through subsidiaries: KBI Biopharma (CDMO for biologics development and manufacturing) and Crown Bioscience (CRO for oncology and immuno-oncology preclinical research).

Is JSR Life Sciences a public or private company?

JSR Life Sciences is a private company. It is classified as corporate owned and is currently operating.

When was JSR Life Sciences founded?

JSR Life Sciences was founded in 2012. It employs 11 to 50 people.

Where is JSR Life Sciences based?

JSR Life Sciences is headquartered in Sunnyvale, United States, in the North America region.

How does JSR Life Sciences make money?

Four revenue lines are on record. Chromatography Resin Sales are the primary driver. The others are contract Research Services (CRO), contract Manufacturing Services (CDMO) and cell Culture Media Products.

Who are JSR Life Sciences's main competitors?

Broad incumbents on record are Cytiva (Danaher), Lonza Group, Samsung Biologics, WuXi Biologics, Catalent (Novo Holdings) and Charles River Laboratories. Direct peers are Tosoh Bioscience, AGC Biologics and MilliporeSigma (Merck KGaA Life Science). Pharmaron is listed as an emerging player.

Does JSR Life Sciences have an API?

No public API is recorded for JSR Life Sciences.

What industry is JSR Life Sciences in?

JSR Life Sciences's product category is Biopharmaceutical CDMO and CRO Services. Its primary akta.pro industry code is HLAGAGAI, Raw Materials & Critical Reagents Supply (Media/Resins/Cytokines), with a secondary code of HLAAAKAI, Raw Materials & Critical Reagents Supply Services (media, resins, single-use). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Jiemian盟科药业:股东Best Idea及JSR等拟合计减持不超6%股份Mengkang Pharmaceutical announced that shareholders Best Idea, JSR, and GP TMT plan to reduce their holdings. Best Idea will sell no more than 19,686,850 shares (3% of total), while JSR and GP TMT together will sell no more than 19,668,162 shares (also 3%), via centralized bidding and block trading.Pulse 2.0Merck: Acquisition Of JSR Life Sciences Chromatography Business CompletedMerck KGaA has completed the acquisition of the chromatography business of JSR Life Sciences through its U.S. and Canada life science arm MilliporeSigma, strengthening its downstream purification capabilities for biopharmaceutical manufacturing. The deal adds advanced Protein A chromatography technologies, including Amsphere Protein A resins, which are critical for purifying monoclonal antibodies used in biologic therapies, along with a Belgium-based team of more than 50 employees. The acquired chromatography business will be incorporated into Merck's Process Solutions portfolio, aiming to help pharmaceutical and biotech manufacturers accelerate production timelines and enhance reliability from development through commercial-scale manufacturing.GlobeNewswireMerck Completes Acquisition of JSR Life Sciences’ Chromatography Business, Expanding Protein A Capabilities and Downstream PortfolioMerck completed the acquisition of JSR Life Sciences' chromatography business, adding Amsphere Protein A resins and advanced chromatography capabilities. The deal integrates a Belgium-based team of over 50 employees into Merck's Process Solutions portfolio, expanding downstream purification for monoclonal antibodies.GlobeNewswireMilliporeSigma Completes Acquisition of JSR Life Sciences’ Chromatography Business, Expanding Protein A Capabilities and Downstream PortfolioMilliporeSigma completed the acquisition of JSR Life Sciences' chromatography business, adding Amsphere Protein A resins and advanced Protein A chromatography capabilities. The deal integrates a Belgium-based team of over 50 employees into MilliporeSigma's Process Solutions portfolio, expanding downstream purification for monoclonal antibodies.MerckgroupMilliporeSigma Completes Acquisition of JSR Life Sciences’ Chromatography BusinessMilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, announced the successful completion of its acquisition of the chromatography business from JSR Life Sciences. The acquisition adds Amsphere Protein A resins and advanced Protein A chromatography capabilities, including a Belgium-based team of more than 50 employees, to MilliporeSigma's downstream processing portfolio. The deal strengthens MilliporeSigma's ability to support scalable purification of monoclonal antibodies and biopharmaceutical manufacturing from development through commercial scale.EIN PresswireProtein Purification and Isolation Market to Reach $15.96 Billion by 2029 with 11.4% CAGRThe global protein purification and isolation market is projected to grow from $9.47 billion in 2024 to $15.96 billion by 2029, representing a compound annual growth rate of 11.4%. Key growth drivers include the expansion of the biologics market, increased funding for life sciences research, rising demand for personalized medicine, and the growth of contract manufacturing organizations. In September 2024, JSR Life Sciences introduced Amsphere A+, a new protein purification product featuring improved binding capacity and alkali stability compared to its predecessor.EIN PresswireChromatography Market to Hit US$ 17.51 Billion by 2033 at 5.7% CAGR | DataM IntelligenceDataM Intelligence released a market report projecting the global chromatography market to reach US$17.51 billion by 2033, growing at a 5.7% CAGR from $10.65 billion in 2024, driven by pharmaceutical R&D expansion, food safety regulations, and biotech growth. The report also aggregates multiple 2025 industry developments including major acquisitions such as Thermo Fisher's $4.1B Solventum deal (completed September 2025) and $9.4B Clario acquisition announcement, Waters' $17.5B reverse-Morris-Trust merger with BD Biosciences, and Merck's agreement to acquire JSR Life Sciences' chromatography business. Asia-Pacific is identified as the fastest-growing region, while North America retains the largest market share.CrownbioJSR Life Sciences Enters Definitive Agreement to Transfer Crown Bioscience to Adicon Holdings LimitedJSR Life Sciences LLC has entered into a definitive agreement to transfer Crown Bioscience Inc. to Adicon Holdings Limited, a Chinese independent clinical laboratory provider and portfolio company of The Carlyle Group, with closing expected in 2026. The transaction will enable Crown Bioscience to operate as a standalone entity under Adicon's ownership, gaining access to Adicon's high-throughput testing and data analytics capabilities alongside Carlyle's healthcare investment expertise. Crown Bioscience's Global Biospecimens business, headquartered in Hamburg, Germany with facilities in Frederick, MD, will remain fully integrated within JSR Life Sciences.